Drug intelligence / Profile preview

BR5402C

Development stage: Unknown
Lead developer: Boryung

Overview

BR5402C is an investigational drug under clinical development for the treatment of schizophrenia. The precise mechanism of action for BR5402C has not been disclosed and remains unknown. It is being evaluated in at least one Phase 2 clinical trial for schizophrenia, with Boryung as the developer. No additional information regarding its pharmacological class, modality, or route of administration has been published in available sources[3][1].

Other names: BR5402CBR-5402CBR 5402C

Beyond the preview

Go deeper on BR5402C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR5402C.

Explore the full profile